盐酸普拉克索结构式
|
常用名 | 盐酸普拉克索 | 英文名 | Pramipexole dihydrochloride |
---|---|---|---|---|
CAS号 | 104632-25-9 | 分子量 | 284.249 | |
密度 | N/A | 沸点 | 378ºC at 760 mmHg | |
分子式 | C10H19Cl2N3S | 熔点 | 288-290ºC | |
MSDS | 美版 | 闪点 | 182.4ºC |
盐酸普拉克索用途Pramipexole双盐酸盐是部分和完全的D2S,D2L,D3和D4受体激动剂, Ki分别为3.9,2.2,0.5和5.1 nM。 |
中文名 | 盐酸普拉克索 |
---|---|
英文名 | pramipexole hydrochloride anhydrous |
中文别名 | S(-)-2-氨基-6-正丙氨基-4,5,6,7-四氢苯并噻唑二盐酸盐 | (S)-普拉克索二盐酸化物 |
英文别名 | 更多 |
描述 | Pramipexole双盐酸盐是部分和完全的D2S,D2L,D3和D4受体激动剂, Ki分别为3.9,2.2,0.5和5.1 nM。 |
---|---|
相关类别 | |
参考文献 |
沸点 | 378ºC at 760 mmHg |
---|---|
熔点 | 288-290ºC |
分子式 | C10H19Cl2N3S |
分子量 | 284.249 |
闪点 | 182.4ºC |
精确质量 | 283.067688 |
PSA | 79.18000 |
LogP | 4.15830 |
外观性状 | 白色结晶粉末 |
蒸汽压 | 6.49E-06mmHg at 25°C |
储存条件 | Desiccate at RT |
危害码 (欧洲) | Xi |
---|---|
危险品运输编码 | NONH for all modes of transport |
海关编码 | 2934999090 |
~84% 盐酸普拉克索 104632-25-9 |
文献:INSTYTUT FARMACEUTYCZNY Patent: WO2007/75095 A1, 2007 ; Location in patent: Page/Page column 7 ; |
~72% 盐酸普拉克索 104632-25-9 |
文献:Ravinder; Rajeswar Reddy; Panasa Reddy; Bandichhor, Rakeshwar Tetrahedron Letters, 2013 , vol. 54, # 36 p. 4908 - 4913 |
~98% 盐酸普拉克索 104632-25-9 |
文献:Helm AG; CF Pharma Gyogyszergyarto Kft. Patent: EP1878731 A1, 2008 ; Location in patent: Page/Page column 11 ; |
~85% 盐酸普拉克索 104632-25-9 |
文献:Helm AG; CF Pharma Gyogyszergyarto Kft. Patent: EP1878731 A1, 2008 ; Location in patent: Page/Page column 11 ; |
~% 盐酸普拉克索 104632-25-9 |
文献:WO2011/21214 A2, ; |
~% 盐酸普拉克索 104632-25-9 |
文献:WO2011/21214 A2, ; |
~% 盐酸普拉克索 104632-25-9 |
文献:WO2011/21214 A2, ; |
~% 盐酸普拉克索 104632-25-9 |
文献:WO2011/21214 A2, ; |
~% 盐酸普拉克索 104632-25-9 |
文献:WO2011/21214 A2, ; |
海关编码 | 2934999090 |
---|---|
中文概述 | 2934999090. 其他杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0% |
申报要素 | 品名, 成分含量, 用途 |
Summary | 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
Pramipexole reduces parkinsonian tremor induced by pilocarpine infusion in the rat striatum.
Pharmacol. Biochem. Behav. 131 , 1-5, (2015) Pramipexole is widely prescribed for the treatment of Parkinson's disease. This dopamine (DA) receptor agonist has a higher affinity for D3 over D2 receptors. We compared the effect of pramipexole to ... |
|
Alterations of BDNF and trkB mRNA expression in the 6-hydroxydopamine-induced model of preclinical stages of Parkinson's disease: an influence of chronic pramipexole in rats.
PLoS ONE 10(3) , e0117698, (2015) Our recent study has indicated that a moderate lesion of the mesostriatal and mesolimbic pathways in rats, modelling preclinical stages of Parkinson's disease, induces a depressive-like behaviour whic... |
|
De novo expression of dopamine D2 receptors on microglia after stroke.
J. Cereb. Blood Flow Metab. 35 , 1804-11, (2015) Dopamine is the predominant catecholamine in the brain and functions as a neurotransmitter. Dopamine is also a potent immune modulator. In this study, we have characterized the expression of dopamine ... |
2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N-propyl-, (6S)-, hydrochloride (1:2) |
(6S)-4,5,6,7-Tetrahydro-N6-propyl-2,6-benzothiazolediamine Dihydrochloride |
(S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole dihydrochloride |
Pramipexole hydrochloride |
Pramipexole dihydrochloride |
MFCD00876894 |
(S)-Pramipexole Dihydrochloride |
(6S)-N-Propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine dihydrochloride |
(S)-N6-Propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine dihydrochloride |
Pramipexole (dihydrochloride) |